The Effectiveness of Group Schema Therapy in the Treatment of Borderline Symptoms in Adolescents
NCT ID: NCT06606002
Last Updated: 2025-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
64 participants
INTERVENTIONAL
2025-08-01
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of a Combined Group-individual Schema Therapy for Borderline Personality Disorder
NCT04211688
Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders
NCT00247234
The Influence of Treatment Format on Schema Therapy for Borderline Personality Disorder
NCT05986552
MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial
NCT02068326
Efficacy of Time-limited Psychodynamic Psychotherapy and Informed Clinical Management in BPD High MHS Users
NCT01356069
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The research sample consists of 32 adolescents who participate in a group schema therapy intervention and their 32 controls. The participants are adolescents aged 15-18 who are being treated at the Adolescent Psychiatry Clinic at the Turku University Hospital. The subjects meet at least three diagnostic criteria for BPD based on SCID-II assessment. Adolescents who are at serious suicide risk or with, for example, psychotic symptoms, or another disorder or symptom that endangers commitment to the intervention protocol, are excluded from the study.
The studied intervention is based on Farrell and Shaw's group schema therapy model. The experiential part of the model is strengthened utilizing videos, which are recorded by the participants (VideoTalk). The videos are used to support both individual and group work. The intervention is tailored to be developmentally sensitive for this age group and reinforced with a module to which the participants' parents participate.
The intervention comprises 30 weekly group sessions and 8 individual sessions. Eight adolescents participate in one group, and four groups are carried out during the study. The participants' parents have 9 group sessions, some of which the adolescents also participate in. The duration of the intervention is approximately one year. The control group receives treatment as usual.
Both the intervention and control groups response to the research questionnaires at five time points (baseline, 3 months, 6 months, 12 months, 2 years). The primary response variable is the change in the BPD symptoms between entering the study and the end of the intervention. As secondary response variables, changes in, for example, the participants' early maladaptive schemas, schema modes, and depressive and anxiety symptoms are assessed. After the end of the intervention, the study includes a one-year follow-up period and two years after the intervention, follow-up data is collected from the participants' medical reports. The study also includes qualitative sub-studies.
The intervention groups will be carried out during the years 2025-2027. A new group is always started overlapping with the previous group. Results regarding the primary response variable will be completed at the end of 2027. The entire research material will be completed at the end of 2029.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group schema therapy
The group schema therapy intervention includes 30 group sessions and 8 individual sessions for the participants, and 9 group sessions for the participants' parents.
Group schema therapy
Group schema therapy based on the model by Farrell and Shaw, which is complemented with separate group sessions for the participants\' parents
Control
Treatment as usual
Treatment as Usual (TAU)
TAU typically comprises visits at the outpatient clinic with variable frequency and content
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group schema therapy
Group schema therapy based on the model by Farrell and Shaw, which is complemented with separate group sessions for the participants\' parents
Treatment as Usual (TAU)
TAU typically comprises visits at the outpatient clinic with variable frequency and content
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The participant and the participant's parent(s) are able to commit to the research protocol for the entire duration of the study
* The participant is able to participate in a research intervention in Finnish and fill out the study questionnaires in Finnish
Exclusion Criteria
* The participant has been diagnosed with an intellectual disability or an autism spectrum disorder
* The main clinical diagnosis of the participant is a substance abuse disorder or substance use would endanger commitment to the research intervention
* The participant has another illness or symptom that endangers the participant's ability to complete the study
* The participant receives some other treatment specifically aimed at borderline personality disorder symptoms
15 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Turku
OTHER
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Max Karukivi
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Max Karukivi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Turku
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku University Hospital
Turku, Southwest Finland, Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T1709/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.